RxDoctor Payments Data

Mitesh Patel, MD

Internal Medicine · Saint Louis, MONPI 1336401942

Payments from drug & device makers

$1,535in general payments, 2019–2025

Across 37 payments — averaging $41.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$361
  • Apollo Endosurgery US Inc$314
  • Johnson & Johnson$172
  • Regeneron Healthcare Solutions, Inc.$154
  • Medtronic$147
  • AbbVie$73
  • plus $315 from 10 others

What the payments were for

  • Grants$292%
  • Food & beverage$1,39591%
  • Education$1127%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,535 in reported general payments places this provider in the 75th percentile of 2,097 internal medicine providers in Missouri.

See all internal medicine providers in Missouri

Medicare billing

Part B allowed, 2024
$85,301
Medicare patients
424
Services billed
659

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
SucraidSacrosidase11$154,589
LinzessLinaclotide68$83,695
CreonLipase/Protease/Amylase17$68,256
XifaxanRifaximin11$27,876
MotegrityPrucalopride Succinate22$23,827
Mesalamine16$8,928
ClenpiqSod Picosulf/Mag Ox/Citric Ac22$4,690
Peg 3350-ElectrolyteSodium Chloride/Nahco3/Kcl/Peg163$3,476
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates49$3,268
Omeprazole159$2,928
Lubiprostone16$2,724
Esomeprazole Magnesium24$2,620
GolytelyPeg3350/Sod Sulf,bicarb,cl/Kcl13$1,563
Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl46$767
Famotidine49$631

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
QOL Medical, LLCSucraid$32$154,58911 claims
AbbVieLinzess, Creon$73$151,95185 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$40$27,87611 claims
Takeda Pharmaceuticals U.S.A., Inc.Motegrity$41$23,82722 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 2,097 internal medicine providers in Missouri.

Other internal medicine in Saint Louis

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →